Glutargyn ampoules concentrate for ifusions 40% 5 ml. №10

Description

Glutargyn ampoules 40% Storage:

active substance: arginine glutamate

1 ml of solution contains 400 mg of arginine glutamate

excipients:

Glutargyn ampoules 40% Dosage form.

Concentrate for solution for infusion.

Glutargyn ampoules 40% Pharmacotherapeutic group.

Drugs used in liver disease are lipotropic substances. Arginine glutamate. ATC code A05B A01.

Clinical characteristics.

Indication. In the complex therapy of acute and chronic hepatitis of various etiologies, including poisoning by hepatotropic poisons (pale toadstool chemicals and drugs) cirrhosis of the liver leptospirosis.

Hepatic encephalopathy precoma and coma accompanied by hyperammonemia.

Acute alcohol poisoning of moderate and severe degree, including alcoholic encephalopathy and coma.

Contraindication.

Hypersensitivity to the components of the drug fever increased excitability, severe impairment of filtration (nitrogen) function of the kidneys.

Method of application and dosage.

The drug is prescribed to adults intravenously.

Hepatitis hyperammonemia.

Alcohol poisoning.

After a course of treatment with 40% Glutargin solution, if necessary, you should switch to taking Glutargin tablets.

Pathology of pregnancy. To enter dropwise 1-2 times a day on 5 ml (2 g) on ​​150-250 ml 0 9% of solution of sodium chloride or 5% of solution of glucose at a rate of 60-70 drops a minute.

Adverse reactions. Rarely possible:

common disorders: shortness of breath chest pain fever fever chills changes at the injection site phlebitis

from the cardiovascular system: atrial fibrillation lowering blood pressure tachycardia

from the digestive system: nausea pain in the epigastric region

from the nervous system: headache dizziness tremor weakness

from the immune system:

Overdose.

Symptoms: increased manifestations of adverse reactions chest pain atrioventricular block.

Treatment: intravenous corticosteroids. Symptomatic therapy.

Use during pregnancy or breastfeeding. The safety of clinical use of the drug during pregnancy in the I and II trimesters of pregnancy and breastfeeding has not been studied.

Children. Efficacy and safety of the drug in children have not been studied.

Features of application.

Ability to influence the speed of reaction when driving a car or working with other mechanisms. No data.

Interaction with other medicinal products and other forms of interaction. The effect of Glutargin on insulin secretion is increased by concomitant administration of aminophylline. Glutargin may potentiate the effect of antiplatelet agents (dipyridamole, etc.). Prevents and alleviates neurotoxic effects that may occur with the use of isoniazid. Weakens the effect of vinblastine.